The molecular classifiers ale needed to determine the oligometastatic PCa patients with a predominantly androgen receptor-driven disease and for whom ADT or abiraterone would constitute an effective treatment as a consequence of adjuvant approach. Here, AR is linked to posterior cortical atrophy.